There is something lurking in the Charleston waterways carrying toxic chemicals, heavy metals, and pathogens: small plastic ...

Gyre Therapeutics, Inc. (GYRE) delivered earnings and revenue surprises of +16.67% and -33.59%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the ...

Full year 2026 revenue guidance of $100.5 to $111.0 million affirmed NDA for F351 (hydronidone) for CHB-associated liver fibrosis submitted to ...

In April 2026, Gyre initiated its adaptive Phase 2/3 clinical trial in oncology-related pulmonary complications, with the first patient enrolled. The trial is evaluating pirfenidone for ...

In today’s creator economy, music drives engagement but also carries legal and monetization risks. From TikTok trends to YouTube uploads, using the right audio source and license is essential to avoid ...

Scientists at the University of Miami have found that sargassum may have a different origin than previously anticipated.

A new study published in Nature Climate Change found that colored microplastics suspended in the atmosphere may contribute ...

,” said Penn. “We’re in this amazing position at the moment where there is a lot of awareness compared to a few years ago, but now we find people saying to us ‘OK, we get there’s a problem and we care ...

SAN DIEGO, March 17, 2026 (GLOBE NEWSWIRE) -- Gyre Therapeutics, Inc. (Gyre or Gyre Therapeutics) (Nasdaq: GYRE), a San Diego-based innovative commercial stage biopharmaceutical company with ...

Gyre Therapeutics has agreed to buy privately held, clinical-stage biopharmaceutical company Cullgen in an all-stock transaction valued at about $300 million, upending plans by Pulmatrix to merge with ...